Analysis of oxidative DNA damage and HPRT mutations in humans after hyperbaric oxygen treatment

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 431, Issue 2, 1999, Pages 351-359

  Dennog, Claudia ^a   Gedik, Catherine ^b   Wood, Sharon ^b   Speit, Günter ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

7,8 Dihydro 8 oxo deoxyguanosine; Comet assay; FPG protein; GST genotypes; HPLC; HPRT mutations; Hyperbaric oxygen; T cell cloning

Indexed keywords

ADULT; ARTICLE; CONFORMATIONAL TRANSITION; DNA CONFORMATION; DNA DAMAGE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN EXPERIMENT; HYPERBARISM; LYMPHOCYTE CLONE; MALE; MOLECULAR CLONING; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; DEOXYGUANOSINE; DNA DAMAGE; DNA-FORMAMIDOPYRIMIDINE GLYCOSYLASE; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; HYPERBARIC OXYGENATION; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MUTATION; N-GLYCOSYL HYDROLASES; OXIDATIVE STRESS;

EID: 0033372078     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00178-5     Document Type: Article

References (41)

1. Dennog C., Hartmann A., Frey G., Speit G. Detection of DNA damage after hyperbaric oxygen (HBO) therapy. Mutagenesis. 11:1996;605-609.
2. Speit G., Dennog C., Lampl L. Biological significance of DNA damage induced by hyperbaric oxygen. Mutagenesis. 13:1998;85-87.
3. Rothfuß A., Dennog C., Speit G. Adaptive protection against the induction of oxidative DNA damage after hyperbaric oxygen treatment. Carcinogenesis. 19:1998;1913-1917.
4. Narkowicz C.H., Vial J.H., McCartney P. Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radical Res. Commun. 19:1993;71-80.
5. Tchou J., Kasai H., Shibutani S., Chung M.H., Laval J., Grollman A.P., Nishimura S. 8-Oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc. Natl. Acad. Sci. USA. 88:1991;4690-4694.
6. Grollman A.P., Moriya M. Mutagenesis by 8-oxoguanine: an enemy within. TIG. 9(7):1993;246-249.
7. Floyd R.A. The role of 8-hydroxyguanine in carcinogenesis Carcinogenesis. 11(9):1990;1447-1450.
8. Loft S., Poulsen H.E. Cancer risk and oxidative damage in man. J. Mol. Med. 74:1996;297-312.
9. Feldmeier J.J., Heimbach R.D., Davolt D.A., Brakora M.J., Sheffield P.J., Porter A.T. Does hyperbaric oxygen have a cancer-causing or promoting effect? A review of the pertinent literature. Undersea Hyperbaric Med. 21:1994;467-475.
10. Cole J., Skopek T.R. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutat. Res. 304:1994;33-105.
11. Albertini R.J., O'Neill J.P. Monitoring for somatic mutations in humans. Phillips D.H., Venitt S. Environmental Mutagenesis. 1995;341-366 ßios Scientific, Oxford.
12. Collins A.R., Dusinska M., Gedik C.M., Stetina R. Oxidative damage to DNA: do we have a reliable biomarker? Environ. Health Perspect. 104(Suppl. 3):1996;465-469.
13. Idle J.R. Is environmental carcinogenesis modulated by host polymorphism? Mutat. Res. 247:1991;259-266.
14. Hayes J.D., Pulford D.J. The glutathione S-Transferase supergene family: regulation of GST and the contribution of the isoezymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30(6):1995;445-600.
15. Hayes J.D., Strange R.C. Potential contribution of the Glutathione S-Transferase supergene family to resistance to oxidative stress. Free Radical Res. 22(3):1995;193-207.
16. Richter C., Park J.W., Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA. 85:1988;6465-6467.
17. Hou S.M., Fält S., Stehen A.M. Hprt mutant frequency and GSTM1 genotype in non-smoking healthy individuals. Environ. Mol. Mutagen. 25:1995;97-105.
18. Albertini R.J., Castle K.L., Borcherding W.R. T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. Proc. Natl. Acad. Sci. USA. 79:1982;6617-6621.
19. Pflaum M., Will O., Epe B. Determination of steady-state levels of oxidative DNA base modifications in mammalian cells by means of repair endonucleases. Carcinogenesis. 18(11):1997;2225-2231.
20. Pouget J.P., Ravanat J.L., Douki T., Richard M.J., Cadet J. Measurement of DNA base damage in cells exposed to low doses of gamma-radiation: comparison between the HPLC-EC and comet assay. Int. J. Radiat. Biol. 75:1999;51-58.
21. Robinson D.R., Goodall K., Albertini R.J., O'Neill J.P., Finette B., Sala-Trepat M., Moustacchi E., Tates A.D., Beare D.M., Green M.H.L., Cole J. An analysis of in vivo mutant frequency in circulating T-lymphocytes in the normal human population: a comparison of four datasets. Mutat. Res. 313:1994;227-247.
22. Cole J., Green M.H.L., James S.E., Henderson L., Cole H. A further assessment of factors influencing measurements of thioguanine-resistant mutant frequency in circulating T-lymphocytes. Mutat. Res. 204:1988;493-507.
23. Jones I.M., Moore D.H., Thomas C.B., Thompson C.L., Strout C.L., Burkhart-Schulz K. Factors affecting HPRT mutant frequency in T-lymphocytes of smokers and nonsmokers. Cancer Epidemiol., Biomarkers Prev. 2:1993;249-260.
24. Branda R.F., Albertini R.J. Effect of dietary components on hprt mutant frequencies in human T-lymphocytes. Mutat. Res. 346:1995;121-127.
25. Duthie S.J., Ross M., Collins A.R. The influence of smoking and diet on the hypoxanthine phosphoribosyltransferase (hprt) mutant frequency in circulating T lymphocytes from a normal human population. Mutat. Res. 331:1995;55-64.
26. Moller P., Wallin H. Adduct formation, mutagenesis and nucleotide excision repair of DNA damage produced by reactive oxygen species and lipid peroxidation product. Mutat. Res. 410:1998;271-290.
27. Ammenheuser M.M., Ward J.B. Jr., Whorton E.B., Killian J.M., Legator M.S. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutat. Res. 204:1988;509-520.
28. Branda R.F., O'Neill J.P., Sullivan L.M., Albertini R.J. Factors influencing mutation at the hprt locus in T-lymphocytes: women treated for breast cancer. Cancer Res. 51:1991;6603-6607.
29. Tates A.D., van Dam F.J., Natarajan A.T., Zwinderman A.H., Osanto S. Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat. Res. 307:1994;293-306.
30. Sanderson B.J.S., Dempsey J.L., Morley A.A. Mutations in human lymphocytes: effect of X- and UV-irradiation. Mutat. Res. 140:1984;223-227.
31. Morley A.A., Trainor K.J., Dempsey J.L., Seshadri R.S. Methods for study of mutations and mutagenesis in human lymphocytes. Mutat. Res. 147:1985;363-367.
32. Bastlová T., Vodicka P., Peterková K., Hemminki K., Lambert B. Styrene oxide-induced HPRT mutations, DNA adducts and DNA strand breaks in cultured human lymphocytes. Carcinogenesis. 16(10):1995;2357-2362.
33. Mei N., Kunugita N., Nomoto S., Norimura T. Comparison of the frequency of T-cell receptor mutants and thioguanine resistance induced by X-rays and ethylnitrosourea in cultured human blood T-lymphocytes. Mutat. Res. 357:1996;191-197.
34. Zimmer D.M., Aaron C.S. In vivo mutagenesis in the cynomolgus monkey: time course of HPRT mutant frequency at long time points following ethylnitrosourea exposure. Environ. Mol. Mutagen. 29:1997;117-123.
35. Gille J.J.P., van Berkel C.G.M., Joenje H. Mutagenicity of metabolic oxygen radicals in mammalian cell cultures. Carcinogenesis. 15(12):1994;2695-2699.
36. Caporaso N. Genetic susceptibility and the common cancers. Biomarkers. 1:1996;174-177.
37. Nebert D.W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist. Am. J. Hum. Genet. 60:1997;265-271.
38. Norppa H. Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ. Health Perspect. 105(Suppl. 4):1997;829-834.
39. Hou S.M., Lambert B., Hemminki K. Relationship between hprt mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis. 16(8):1995;1913-1917.
40. Bell D.A., Taylor J.A., Paulson D.F., Robertson C.N., Mohler J.L., Lucier G.W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl. Cancer Inst. 85:1993;1159-1164.
41. Gonzalez F.J. Xenobiotic-metabolizing enzymes in biomarker research. Mendelsohn M.L., Peeters J.P., Normandy M.J. Biomarkers and Occupational Health. 1995;133-139 Joseph Henry Press, Washington D.C.